372183-70-5

Basic information

• Product Name: 2-CHLORO-4-[2-(4-FLUOROPHENYL)ETHYL]-6-METHYLPYRIMIDINE
• Synonyms: 2-CHLORO-4-[2-(4-FLUOROPHENYL)ETHYL]-6-METHYLPYRIMIDINE
• CAS NO: 372183-70-5
• Molecular Formula: C₁₂H₁₂ClN₃
• Molecular Weight: 250.7
• Mol File: 372183-70-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 449.6°C at 760 mmHg
• Flash Point: 225.7°C
• Appearance: /Solid
• Density: 1.296g/cm³
• Vapor Pressure: 2.81E-08mmHg at 25°C
• Refractive Index: 1.607
• PKA: 3.48±0.10(Predicted)
• CAS DataBase Reference: 2-CHLORO-4-[2-(4-FLUOROPHENYL)ETHYL]-6-METHYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-4-[2-(4-FLUOROPHENYL)ETHYL]-6-METHYLPYRIMIDINE(372183-70-5)
• EPA Substance Registry System: 2-CHLORO-4-[2-(4-FLUOROPHENYL)ETHYL]-6-METHYLPYRIMIDINE(372183-70-5)

Safety Data

• Hazardous Substances Data: 372183-70-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H13ClFN3/c1-9-8-12(18-13(14)17-9)16-7-6-10-2-4-11(15)5-3-10/h2-5,8H,6-7H2,1H3,(H,16,17,18)

Upstream product

• 64-04-0 phenethylamine 
• 97229-10-2 4-chloro-2-(methylsulfinyl)pyrimidine 
• 3934-20-1 2,6-Dichloropyrimidine 

Downstream Products

• 317824-84-3 2-[(S)-1-Phenylethylamino]-4-[5,6-dichlorobenzimidazol-1-yl]pyrimidine 
• 1201173-75-2 4-(4-methylpiperazin-1-yl)-N-phenethylpyrimidin-2-amine 

Relevant articles and documents

Discovery of a Novel and Brain-Penetrant O-GlcNAcase Inhibitor via Virtual Screening, Structure-Based Analysis, and Rational Lead Optimization

O-GlcNAcase (OGA) has received increasing attention as an attractive therapeutic target for tau-mediated neurodegenerative disorders; however, its role in these pathologies remains unclear. Therefore, potent chemical tools with favorable pharmacokinetic profiles are desirable to characterize this enzyme. Herein, we report the discovery of a potent and novel OGA inhibitor, compound 5i, comprising an aminopyrimidine scaffold, identified by virtual screening based on multiple methodologies combining structure-based and ligand-based approaches, followed by sequential optimization with a focus on ligand lipophilicity efficiency. This compound was observed to increase the level of O-GlcNAcylated protein in cells and display suitable pharmacokinetic properties and brain permeability. Crystallographic analysis revealed that the chemical series bind to OGA via characteristic hydrophobic interactions, which resulted in a high affinity for OGA with moderate lipophilicity. Compound 5i could serve as a useful chemical probe to help establish a proof-of-concept of OGA inhibition as a therapeutic target for the treatment of tauopathies.